Praetego’s candidates are called ‘Amadorins’. These proprietary small molecules are unique inhibitors of the oxidative breakdown of proteins modified by glucose (Amadori products). This non-enzymatic process forms byproducts called Advanced Glycation End-products, or AGEs. In the AGE pathway, AGE formation and accumulation leads to diabetic microvascular disease. In diabetic patients, these glucose-mediated reactions damage blood vessels, nerves, the retina, and kidney. The AGE pathway is a powerful instigator of oxidative stress. This mechanism of damage is also active in cardiovascular disease and neurodegeneration.
The Amadorins inhibit AGE formation at its earliest stages. By interrupting the pathway at the first step of oxidative breakdown, Amadorins offer the greatest promise of protection against serious diabetic complications.